...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Are We There Yet? Laboratory Preparedness for Emerging Infectious Diseases
【24h】

Are We There Yet? Laboratory Preparedness for Emerging Infectious Diseases

机译:我们到了吗?实验室应对新发传染病的准备

获取原文
           

摘要

The West African Ebola virus epidemic of 2013a??2016 was the most widespread epidemic of this disease in history; it is estimated that this occurrence contributed to more than 11000 deaths. During the epidemic, healthcare workers (HCW)8 (including laboratorians) were mobilized to care for individuals with suspected or confirmed Ebola virus disease (EVD). However, at the height of the epidemic, guidance on appropriate safety measures for laboratory workers manipulating specimens from EVD patients was sparse. This highlighted the need for data and guidelines for laboratories testing specimens not only for patients with EVD, but for any emerging infectious disease. During the Ebola epidemic, questions were raised about the roles and responsibilities of laboratories in responding to highly infectious diseases, and the burden of ongoing readiness for rare events. As the outbreak decelerates, laboratorians must regroup, gather data, and prepare for future outbreaks. We have asked 4 experts in this field to share their thoughts on contemporary challenges in laboratory preparedness for emerging infectious diseases. During the recent Ebola epidemic, what laboratory testing did your hospital offer for patients with suspected EVD? Who performed this testing and where was the testing performed? Did you have dedicated equipment for laboratory testing or did you utilize existing core laboratory equipment? Eileen Burd: Patients with clinical symptoms and appropriate epidemiologic risk factors for EVD were stratified as high, intermediate, or low risk by the provider seeing the patient. If evaluation revealed low risk or no identifiable risk, standard tests were generally ordered that included tests for diagnoses other than EVD including complete blood count (CBC) with differential, complete metabolic profile (CMP), and malaria testing. Other tests that were ordered as indicated by the patient's symptoms included blood cultures, respiratory virus testing, urinalysis, urine culture, and molecular gastrointestinal panels. Blood and other specimens were collected a?|
机译:2013a-2016年的西非埃博拉病毒流行是该病历史上最广泛的流行;据估计,这种情况造成了超过11000人死亡。在流行期间,动员了医护人员(HCW)8(包括实验室工作人员)照顾患有可疑或确诊的埃博拉病毒病(EVD)的个体。但是,在疫情最严重的时候,针对实验室工作人员操作EVD患者标本的适当安全措施的指导很少。这突出表明,不仅需要为EVD患者,而且还应针对任何正在出现的传染病,为实验室检测标本提供数据和指南。在埃博拉疫情期间,有人质疑实验室在应对高传染性疾病方面的作用和责任,以及为罕见事件持续做好准备的负担。随着疫情减速,实验室人员必须重新组合,收集数据并为将来的疫情做好准备。我们邀请了该领域的4位专家分享他们对实验室应对新发传染病的当代挑战的想法。在最近的埃博拉疫情期间,您的医院为可疑EVD患者提供了哪些实验室检查?谁进行了这项测试,测试在哪里进行?您是否拥有用于实验室测试的专用设备,或者您是否在利用现有的核心实验室设备?艾琳·伯德(Eileen Burd):具有临床症状和适当的EVD流行病学危险因素的患者,通过提供者的观察将患者分为高,中或低风险。如果评估显示低风险或无可识别风险,则通常应订购标准测试,包括除EVD以外的诊断测试,包括全血细胞计数(CBC)以及差异,完全代谢谱(CMP)和疟疾测试。根据患者症状指示进行的其他检查包括血液培养,呼吸道病毒检测,尿液分析,尿培养和分子胃肠道检查。采集血液和其他标本吗?

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号